
AKN-028
CAS No. 1175017-90-9
AKN-028 ( —— )
产品货号. M28189 CAS No. 1175017-90-9
AKN-028 是一种口服有效的 FLT3 酪氨酸激酶抑制剂 (IC 50 = 6 nM)。 AKN-028 会导致 FLT3 自磷酸化的剂量依赖性抑制。
纯度: >98% (HPLC)






规格 | 价格/人民币 | 库存 | 数量 |
5MG | ¥721 | 有现货 |
![]() ![]() |
10MG | ¥1223 | 有现货 |
![]() ![]() |
25MG | ¥2527 | 有现货 |
![]() ![]() |
50MG | ¥3969 | 有现货 |
![]() ![]() |
100MG | ¥5792 | 有现货 |
![]() ![]() |
200MG | 获取报价 | 有现货 |
![]() ![]() |
500MG | 获取报价 | 有现货 |
![]() ![]() |
1G | 获取报价 | 有现货 |
![]() ![]() |
生物学信息
-
产品名称AKN-028
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述AKN-028 是一种口服有效的 FLT3 酪氨酸激酶抑制剂 (IC 50 = 6 nM)。 AKN-028 会导致 FLT3 自磷酸化的剂量依赖性抑制。
-
产品描述AKN-028 is an orally active and potent FLT3 tyrosine kinase inhibitor ( IC 50 = 6 nM). AKN-028 causes dose-dependent inhibition of FLT3 autophosphorylation.(In Vitro):AKN-028 triggers apoptosis in MV4-11 by activation of caspase 3 . AKN-028 (10 μM) is cytotoxic to AML cell lines and induces apoptosis in the AML cell line MV4-11 . Cell Cytotoxicity Assay Cell Line: AML cell line MV4-11. Concentration: 10 μM. Incubation Time: 24 h. Result: Was cytotoxic to primary AML cells, irrespective of FLT3 mutation status and quantitative FLT3 expression.(In Vivo):AKN-028 (15?mg/kg, Subcutaneously injection twice daily) exhibits anti-tumor activities for acute myeloid leukemia (AML) models . Animal Model: Mice based AML and MV4-11 cells . Dosage: 15?mg/kg. Administration: Subcutaneously injection twice daily. Result: Inhibited net growth of one of the primary AML samples (UPN26) in vivo and furthermore reduced the tumor mass of MV4-11 cell line.
-
体外实验AKN-028 (0.1 nM-100 μM; 15 h; mouse embryonal fibroblasts and human acute megakaryoblastic leukemia M07 cells) inhibits FLT3 and KIT autophosphorylation in a dose-dependent manner.AKN-028 (10 μM; 72 h; tumor cell lines) is cytotoxic to AML cell lines and induces apoptosis in the AML cell line MV4-11. Western Blot Analysis Cell Line:Mouse embryonal fibroblasts either overexpressing FLT-wt, FLT3-TKD or FLT3-ITD and human acute megakaryoblastic leukemia M07 cells overexpressing KIT Concentration:0.1 nM-100 μM Incubation Time:15 hours Result:Inhibited FLT3 and KIT autophosphorylation.Cell Cytotoxicity Assay Cell Line:Tumor cell lines Concentration: 10 μM Incubation Time:72 hours Result:Had cytotoxic activity was highest in MV4-11 and MOLM-13 (IC50<50?nM), followed by the three other AML cell lines (IC50=0.5-6?μM).
-
体内实验AKN-028 (15?mg/kg; i.h.; twice daily, for 6 days; male C57 black mice with MV4-11 xenografts) inhibits growth of primary AML and MV4-11 cells in mice. Animal Model:Male C57 black mice with MV4-11 xenografts Dosage:15 mg/kg Administration:Subcutaneous injection; twice daily, for 6 days Result:Inhibited tumor growth and did not affect body weight.
-
同义词——
-
通路Angiogenesis
-
靶点FLT
-
受体——
-
研究领域——
-
适应症——
化学信息
-
CAS Number1175017-90-9
-
分子量302.33
-
分子式C17H14N6
-
纯度>98% (HPLC)
-
溶解度In Vitro:?DMSO : 125 mg/mL (413.46 mM)
-
SMILESNC1=NC=C(N=C1NC1=CC=C2NC=CC2=C1)C1=CC=NC=C1
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Morita M, et al. Preliminary preformulation studies of a 2-(3,4-dimethoxyphenyl)ethylamine derivative for oral administration at an exploratory stage of new drug development. Chem Pharm Bull (Tokyo). 1995 Mar;43(3):476-82.
产品手册




关联产品
-
7BIO
7-bromoindirubin-3'-oxime (7BIO) 是一种不依赖半胱天冬酶的非凋亡细胞死亡诱导剂。 7BIO 是 FLT3、DYRK1A、DYRK2、Aurora B 和 Aurora C 激酶的抑制剂。
-
Pacritinib
Pacritinib (SB1518) 是 Janus Kinase 2 (JAK2) 和 Fms-Like Tyrosine Kinase-3 (FLT3) 的有效选择性抑制剂,在无细胞测定中 IC50 分别为 23 和 22 nM。
-
(E/Z)-Zotiraciclib
(E/Z)-Zotiraciclib 有效抑制 CDK2、JAK2 和 FLT3,IC50 分别为 13、73 和 56 nM。